Osimertinib Drugs Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The osimertinib drugs market size has grown rapidly in recent years. It will grow from $6.66 billion in 2024 to $7.82 billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to r&d investment and innovation, targeted therapy introduction, clinical trial success, resistance to previous treatments, improved safety profile.

The osimertinib drugs market size is expected to see rapid growth in the next few years. It will grow to $14.05 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to patient-centric care enhancement, continued clinical trials and research, precision medicine integration, pricing and access initiatives, global market expansion. Major trends in the forecast period include biosimilar entry and market competition, liquid biopsy adoption, genomic profiling advancements, resistance management strategies, immunotherapy combination trials.

The anticipated rise in the incidence of lung cancer is set to drive the growth of the osimertinib drug market. Lung cancer, originating in the lung tissues, particularly in cells lining the airways, is a target for osimertinib, a therapeutic drug that blocks specific proteins involved in the growth and spread of cancer cells. According to the American Cancer Society, the United States witnessed around 236,740 diagnosed lung cancer cases in 2022, a number that has increased to 238,340 by 2023. Consequently, the escalating incidence of lung cancer stands as a significant factor propelling the osimertinib drug market's growth.

The growing initiatives from organizations aimed at enhancing lung cancer care and treatment are anticipated to significantly drive the growth of the osimertinib drug market in the coming years. These initiatives typically involve the implementation of policies, funding, and programs designed to improve the accessibility, affordability, and quality of care for individuals diagnosed with lung cancer. For instance, in May 2024, the Australian Department of Health and Aged Care launched the National Lung Cancer Screening Program (NLCSP), which employs a structured approach for the early detection of lung cancer using low-dose computed tomography (LDCT) scans. This program specifically targets high-risk individuals, particularly those aged 50 to 80 with a substantial smoking history. Such organizational efforts to optimize the utilization of osimertinib, a targeted therapy for lung cancer, highlight the commitment to improving treatment outcomes. Therefore, these initiatives are propelling the growth of the osimertinib drug market.

Major companies in the osimertinib drugs market are increasingly focused on targeted therapies to enhance outcomes for patients with non-small cell lung cancer (NSCLC), especially those harboring EGFR mutations. This focus aims to improve treatment effectiveness and the overall quality of life for patients. Companies are also dedicating resources to clinical trials and research collaborations to broaden the indications for osimertinib and assess its efficacy in combination with other therapies for more comprehensive patient benefits. For instance, in September 2024, AstraZeneca Pharmaceuticals LP announced the launch of osimertinib (Tagrisso) for adults with locally advanced, unresectable NSCLC with specific EGFR mutations, following FDA approval. This approval came after a clinical trial showed significant improvements in progression-free survival compared to placebo, underscoring the potential of osimertinib as a vital treatment option for this patient population.

In October 2022, Ikena Oncology collaborated with AstraZeneca to explore the potential combination of IK-930 and osimertinib for enhanced efficacy and safety in treating EGFR-mutated non-small-cell lung cancer (NSCLC). This collaboration is a strategic move to leverage the expertise of both companies in advancing treatment options.

Major companies operating in the osimertinib drugs market report are Syndax Pharmaceuticals Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, AstraZeneca PLC, Amgen Inc., Sandoz International GmbH, Incyte Corporation, Dr. Reddy's Laboratories Ltd., Cipla Limited, Seagen Inc., Zydus Lifesciences Limited, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Aristo Pharmaceuticals Private Limited, Incepta Pharmaceuticals Ltd., Accord Healthcare Limited, Asmo Corporation, Beacon Pharmaceutical Limited, Clearsynth Labs Limited, Apino Pharma Co. Ltd., Kay Biotech Private Limited, Drug International Limited, MSN Laboratories Pvt Ltd., Array BioPharma Inc., Dolphin Pharmaceutical Limited, Hetero Drugs Ltd., Serum Biotech Limited, Zenix Remedies, Accure Labs Pvt. Ltd.

North America was the largest region in the osimertinib drugs market in 2024. The regions covered in the osimertinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the osimertinib drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osimertinib drugs market consists of sales of tagrisso, osi-TKI, and osimertinib mesylate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Osimertinib is a medication prescribed for the treatment of non-small cell lung cancer (NSCLC) in patients with specific abnormal epidermal growth factor (EGFR) genes. As a kinase inhibitor, it functions by blocking the action of the abnormal protein that signals cancer cells to multiply.

The main types of osimertinib drugs are available in 40mg and 80mg dosages. The 40mg designation represents the strength of the Osimertinib tablet. These medications are distributed through various channels, including hospital pharmacies, drugstores, retail pharmacies, and online pharmacies, catering to conditions such as locally advanced non-small cell lung cancer (NSCLC), metastatic non-small cell lung cancer (NSCLC), and others.

The osimertinib drugs market research report is one of a series of new reports that provides osimertinib drugs market statistics, including osimertinib drugs industry global market size, regional shares, competitors with an osimertinib drugs market share, detailed osimertinib drugs market segments, market trends and opportunities, and any further data you may need to thrive in the osimertinib drugs industry. This osimertinib drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.